FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

News

Alberta To Issue 250 Cannabis Store Licences In 1st Year Of Operation

Alberta To Issue 250 Cannabis Store Licences In 1st Year Of Operation
Alberta To Issue 250 Cannabis Store Licences In 1st Year Of Operation Employees also will have to get background checks and take a workshop. Alberta Justice Minister Kathleen Ganley provides details of the proposed cannabis legislation in Edmonton on Nov. 16, 2017. EDMONTON — Alberta expects to issue 250 licences for cannabis stores in the first year…
Read more

PreveCeutical Signs Research and Option Agreement with UniQuest Pty Limited for Development of Non-Addictive Analgesic Peptides

PreveCeutical Signs Research and Option Agreement with UniQuest Pty Limited for Development of Non-Addictive Analgesic Peptides
PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that, further to its news release dated August 8, 2017, it has entered into a research and option agreement (the “Research Agreement”), with the University of Queensland (“UQ”) and UniQuest Pty Limited (“UniQuest”), UQ’s main commercialisation company. Pursuant to the Research Agreement, the parties intend to conduct a research program (the “Research Program”) which expands the use of their disulfide linker technology and seeks to develop non-addictive analgesics for the treatment of pain, which may offer an alternative to addictive opioids. The opioid epidemic has led to significant numbers of opioid-related deaths and addictions, taxing public health care systems and affecting social and economic welfare.
Read more

PreveCeutical signs Research and Option Agreement with UniQuest Pty Limited for Developing Dual-Gene Therapy Treatment for Diabetes and Obesity

PreveCeutical signs Research and Option Agreement with UniQuest Pty Limited for Developing Dual-Gene Therapy Treatment for Diabetes and Obesity
PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV) announces, further to its news release dated April 13, 2017, that it has entered into a research and option agreement through an agreement made effective as of July 14, 2017 (the “Research Agreement”) between its wholly-owned subsidiary, PreveCeutical Medicals Holdings Inc., and UniQuest Pty Limited (“UniQuest”), the main commercialization company for the University of Queensland (“UQ”), to conduct a research program (the “Research Program”) focused on the development of Smart-siRNAs for the treatment of diabetes and obesity. This will be the third research and option agreement between PreveCeutical and UniQuest.
Read more